| Estimated life expectancy and income of patients with sickle cell disease compared with those without sickle cell disease D Lubeck, I Agodoa, N Bhakta, M Danese, K Pappu, R Howard, ... JAMA network open 2 (11), e1915374-e1915374, 2019 | 303 | 2019 |
| Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States A Stopeck, M Rader, D Henry, M Danese, M Halperin, Z Cong, Y Qian, ... Journal of medical economics 15 (4), 712-723, 2012 | 67 | 2012 |
| The generalized data model for clinical research MD Danese, M Halperin, J Duryea, R Duryea BMC medical informatics and decision making 19, 1-13, 2019 | 34 | 2019 |
| Cost‐effectiveness of onabotulinumtoxinA for the treatment of wrist and hand disability due to upper‐limb post‐stroke spasticity in S cotland QV Doan, P Gillard, A Brashear, M Halperin, E Hayward, S Varon, ZJ Lu European Journal of Neurology 20 (5), 773-780, 2013 | 34 | 2013 |
| Estimating the population benefits and costs of rituximab therapy in the United States from 1998 to 2013 using real-world data MD Danese, CM Reyes, ML Gleeson, M Halperin, SL Skettino, J Mikhael Medical care 54 (4), 343-349, 2016 | 25 | 2016 |
| Refining the definition of clinically important mineral and bone disorder in hemodialysis patients MD Danese, M Halperin, KA Lowe, BD Bradbury, TP Do, GA Block Nephrology Dialysis Transplantation 30 (8), 1336-1344, 2015 | 16 | 2015 |
| PCN116 cost-effectiveness of denosumab versus zoledronic acid (ZA) for the prevention of skeletal-related events (sre) in patients with bone metastases from solid tumors in the … M Lothgren, A Bracco, B Lucius, K Northridge, M Halperin, D Macarios, ... Value in Health 14 (7), A455, 2011 | 14 | 2011 |
| Societal costs of sickle cell disease in the United States I Agodoa, D Lubeck, N Bhakta, M Danese, K Pappu, R Howard, ... Blood 132, 4706, 2018 | 10 | 2018 |
| Fibroblast growth factor 23 as a risk factor for cardiovascular events and mortality in patients in the EVOLVE trial GA Block, GM Chertow, K Cooper, S Xing, B Fouqueray, M Halperin, ... Hemodialysis International 25 (1), 78-85, 2021 | 7 | 2021 |
| Quality adjusted life year gains associated with administration of recombinant tissue-type plasminogen activator for treatment of acute ischemic stroke: 1998–2011 DP Lubeck, MD Danese, J Duryea, M Halperin, D Tayama, E Yu, D Lalla, ... International Journal of Stroke 11 (2), 198-205, 2016 | 4 | 2016 |
| Skeletal-related events (SRE) prevented in breast cancer patients with bone metastases in the United States (US) J Arellano, K Chen, M Halperin, M Danese CANCER RESEARCH 73, 2013 | 2 | 2013 |
| Cost-effectiveness of denosumab (Dmab) versus zoledronic acid (ZA) for prevention of skeletal-related events (SREs) in patients (pts) with castrate-resistant prostate cancer … ME Rader, M Danese, Z Cong, M Halperin, Y Qian, CD Goessl, K Chung Journal of Clinical Oncology 30 (5_suppl), 59-59, 2012 | 1 | 2012 |
| Clinical and economic outcomes associated with emergency department visits in patients with immune thrombocytopenia ZJ Lu, MD Danese, M Halperin, M Eisen, R Deuson Blood 118 (21), 4209, 2011 | 1 | 2011 |
| PCN26 BUDGET IMPACT MODEL OF DENOSUMAB FOR SKELETAL RELATED EVENT (SRE) PREVENTION IN PATIENTS WITH BREAST AND PROSTATE CANCER K Northridge, A Richhariya, M Halperin, K Chung, MD Danese Value in Health 14 (3), A159, 2011 | 1 | 2011 |
| Modeling longer-term efficacy of neratinib in the extended adjuvant setting for early-stage breast cancer. MD Danese, M Halperin, D Lalla, B Yao, J Crown, QV Doan Journal of Clinical Oncology 37 (15_suppl), e12011-e12011, 2019 | | 2019 |
| Modeling the consequences of recurrences after trastuzumab treatment of HER2+ early-stage breast cancer. QV Doan, M Martin, D Lalla, M Halperin, R Bryce, MD Danese, B Moy Journal of Clinical Oncology 37 (15_suppl), e12032-e12032, 2019 | | 2019 |
| Population effectiveness model of the consequences of recurrences following treatment with trastuzumab among women with HER2+ early stage breast cancer in the United States Q Doan, M Martin, D Lalla, M Halperin, B Barnett, R Bryce, M Danese, ... The Breast 44, S19, 2019 | | 2019 |
| Years of Life Lost and Lifetime Earnings Lost in Metastatic Lung Cancer: Potential Societal Benefits of Improved Survival by Age and Histology B Korytowsky, K Kulig, M Halperin, MD Danese JOURNAL OF THORACIC ONCOLOGY 10 (9), S272-S272, 2015 | | 2015 |
| Projected long-term clinical, economic, falls and driving loss outcomes of brimonidine vs. timolol in a US population of normal-tension glaucoma patients W Wong, QV Doan, M Halperin, J Duryea Investigative Ophthalmology & Visual Science 56 (7), 2130-2130, 2015 | | 2015 |
| Potential Impact of New Generation Immunotherapy on Years of Life Lost and Lifetime Earnings in Metastatic Melanoma K Kulig, C De Moor, B Korytowsky, M Halperin, M Danese Annals of Oncology 25, iv359, 2014 | | 2014 |
